Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Ambros, Peter F*" or (type exact bookEditor and editor="Ambros, Peter F*")

Add to list
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F. Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R. Betts, et al.

(2021) JOURNAL OF CLINICAL ONCOLOGY. 39(30). p.3377-3390
Add to list
- Journal Article
- A1
- open access
Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study

Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas Matthyssens (UGent) , et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(25). p.2902-2916
Add to list
- Journal Article
- A1
- open access
Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Pauline Depuydt, Valentina Boeva, Toby D Hocking, Robrecht Cannoodt (UGent) , Inge M Ambros, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2018) JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 110(10).
Add to list
- Conference Paper
- C3
Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients

Pauline Depuydt, Valentina Boeva, Toby D Hocking, Robrecht Cannoodt (UGent) , Inge M Ambros, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2017) Cancer Genomics, 3rd EACR conference, Abstracts.
Add to list
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D. J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys (UGent) , Josef Malis, et al.

(2017) LANCET ONCOLOGY. 18(4). p.500-514
Add to list
- Conference Paper
- C3
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients

Pauline Depuydt, Valentina Boeva, Toby D Hocking, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, Matthias Fischer, Michael D Hogarty, et al.

(2016) Advances in Neuroblastoma Research, Congress abstracts.
Add to list
A multilocus technique for risk evaluation of patients with neuroblastoma

Inge M Ambros, Bettina Brunner, Gerhard Aigner, Clare Bedwell, Klaus Beiske, Jean Bénard, Nick Bown, Valerie Combaret, Jerome Couturier, Raffaella Defferrari, et al.

(2011) CLINICAL CANCER RESEARCH. 17(4). p.792-804
Add to list
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Joëlle Vermeulen (UGent) , Katleen De Preter (UGent) , Arlene Naranjo, Liesbeth Vercruysse (UGent) , Nadine Van Roy (UGent) , Jan Hellemans, Katrien Swerts (UGent) , Sophie Bravo, Paolo Scaruffi, Gian Paolo Tonini, et al.

(2009) LANCET ONCOLOGY. 10(7). p.663-671
Add to list
Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics

Jo Vandesompele (UGent) , Evi Michels (UGent) , Katleen De Preter (UGent) , Björn Menten (UGent) , Alexander Schramm, Angelika Eggert, Peter F Ambros, Valérie Combaret, Nadine Francotte, Francesca Antonacci, et al.

(2008) INTERNATIONAL JOURNAL OF CANCER. 122(5). p.1177-1182

Academic Bibliography

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study

Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients

A multilocus technique for risk evaluation of patients with neuroblastoma

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics

Contents

Support

Contact